SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of JPMorgan Chase & Co. – JPM

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of JPMorgan Chase & Co. (“JPMorgan” or the “Company”) (NYSE: JPM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether JPMorgan and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On November 6, 2018, the U.S. Department of Justice (“DOJ”) announced in a press release that former JPMorgan precious metals trader John Edmonds had pled guilty to commodities fraud and spoofing conspiracy—i.e., placing larger orders with no intention of executing, thereby creating an artificial impression of high demand or supply of the commodity in question. Then, on August 20, 2019, the DOJ announced that another JPMorgan employee, Christian Trunz, pled guilty to spoofing charges, admitting that he had learned to spoof from more senior traders and had engaged in spoofing with the knowledge and consent of his supervisors. On September 23, 2020, Bloomberg reported that the Company was nearing a settlement to resolve the spoofing charges, stating that JPMorgan was “poised to pay close to $1 billion.” On this news, JPMorgan’s stock price fell $2.04 per share, or 2.15%, to close at $92.74 per share on September 23, 2020. Finally, on September 29, 2020, the Commodity Futures Trading Commission formally announced that it had ordered JPMorgan to pay $920 million to settle spoofing and market manipulation charges.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

Mavenlink Recognized as Best Place to Work for Its Exceptional Work Environment

Professional Services Industry Leader Earns Multiple Accolades for Workplace Culture and Commitment to Employee Well-Being

IRVINE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Mavenlink, the leading provider of cloud-based software for the modern services organization, has been recognized for its response to the COVID-19 pandemic; its positive, high-trust culture; its executive involvement; and, its benefits and compensation offerings.

“At Mavenlink, we believe it’s especially important to build a workplace environment that prioritizes employee well-being, safety, collaboration, and transparency, especially through times of crisis,” said Ray Grainger, CEO and co-founder, Mavenlink. “The pandemic has been challenging for so many industries. Fortunately, we have persevered in large part due to the strong culture we have built. We look forward to continuing to build a workplace culture that people are excited to join and be a part of.”

Four recent accolades celebrate the organization’s commitment to creating a positive and inclusive work environment. The awards received include: The Comparably Award for Best Compensation, Orange County Business Journal Best Places to Work recognition, a Great Place to Work Certification, and a Stevie International Business Award® for COVID Most Valuable Corporate Response, which exemplify Mavenlink as an employee-centric organization.

Mavenlink Award Winning Response to COVID

Mavenlink received a Stevie International Business Award for the Most Valuable Corporate Response for COVID. The award recognizes organizations that provided “exemplary responses by companies to the pandemic to ensure the well-being of their employees, customers, and communities.”

The Mavenlink three-step prepare, response, recover plan to support employees received the high average scores from Stevie judges. One judge noted that Mavenlink, “clearly demonstrated that [it is] a caring employer and the employees have very strongly endorsed [the company’s] efforts. Good lines of communication and dialogue is the key to corporate success and [Mavenlink has] been exemplary in this regard.”

Mavenlink Company Culture Highlighted in “Best of” Award Wins

Mavenlink’s quick and efficient high-impact COVID response plan underscores the strong cultural foundation already present within the organization. Implementing rigid protocols during a challenging time requires buy-in, and awards for a “best of” workplace demonstrate the strong employee community that exists. Workplace awards Mavenlink recently received include:

  • Comparably Award for Q3 2020: Best Compensation. Comparably provides the most comprehensive and accurate representation of what it’s like to work at companies. The organization awarded Mavenlink this accolade based on anonymous employee sentiment ratings to questions about compensation satisfaction.
  • Great Place to Work Certification. This recognition from Great Place to Work and Fortune signifies that Mavenlink has built a “high-trust, positive workplace culture for [its] employees.” The certification process revealed that 95% of Mavenlink employees rate the company as a great place to work and comment positively on the people, the team, and the leadership.
  • Orange
    County Business Journal Best Places to Work. Each year, the Business Journal highlights local organizations that are great places to work and also benefit the economy and workforce. The Business Journal awarded Mavenlink based on employee surveys and an evaluation of workforce demographics. Mavenlink stood out for practices, such as its family-friendly benefits policies, regular CEO-led meetings, and employee recognition programs.

“Mavenlink is proud of the recognition it has received,” continued Grainger. “Our employees are dedicated to our customers, as well as to one another, and the communities we serve.”

Visit Mavenlink to learn more about the company culture.
For more information about Mavenlink careers, please visit Mavenlink.

About Mavenlink

Mavenlink is the modern software platform for professional and marketing services organizations. It is the only solution that helps services firms establish an operational system of record that facilitates their business lifecycle, including key capabilities like resource management, project management, collaboration, project accounting, and Business Intelligence. Services organizations in more than 100 countries are improving operational execution, increasing agility, and driving improved financial performance with Mavenlink. Mavenlink was named one of the fastest growing companies in North America by Deloitte, is the first solution to be listed as a Leader in both G2 Crowd’s Best Professional Services Automation and Best Project Management Software grids, and has been recognized as a Glassdoor Best Place to Work. Learn more at www.mavenlink.com.

Contact: [email protected]

Clean Earth Projected to Process 13M+ Aerosol Cans in 2020, Breaking Previous Record


  • Clean Earth
    processed nearly 1 Million
    cans
    each
    month in 2020 and expects to reach 1
    3
    M
    illion
    by the end of the year
    , setting
    a
    new
    C
    ompany record.



  • Clean Earth
    will be expanding capabilities to meet growing demand a
    dding to
    the
    C
    ompany’s vast specialty waste network.

HATBORO, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) — Clean Earth, one of the largest specialty waste companies in the United States, today announced that its Clean Earth Aerosol Recycling System expects to process 13 million aerosol cans by the end of 2020, an 85% increase from the company’s aerosol can recycling in 2015. Leading the field in advanced, sustainable aerosol recycling for pressurized steel cans, aluminum cans, plastics and glass, Clean Earth has already surpassed their record year in 2017.

This milestone is a direct result of Clean Earth’s proven history of Final Rule compliance, health and safety initiatives and the Company’s one-of-a-kind recycling system technology, specifically designed to service all industries that produce aerosol, loose spec paint and other consumer commodity waste. Clean Earth commits to ensuring that 100 percent of each can goes through the recycling process, as well as to zero landfilling, carbon footprint reduction, no long-term degradation exposure to the environment, and cost-effective, customized solutions for every customer.

Clean Earth ranks number one among specialty waste organizations with 19 transfer, storage and disposal facilities (TSDFs) and proven technology that allows for efficient processing of aerosol cans. Clean Earth’s key to success is its hazardous waste facility in Morgantown, West Virginia that processes aerosol cans received from coast to coast.

Nearly 3 billion aerosol cans are produced in the U.S. each year. Morgantown’s sophisticated and robust processing systems are designed specifically to manage aerosol waste and Clean Earth’s network is projected to expand with additional recycling processing units by 2022.

“It’s exciting to have bypassed one of our core company goals this year for the Aerosol Recycling System, which was the processing of 11.4 million aerosol cans, by millions to reach this milestone today,” said Clean Earth Vice President of Operations Hector Sanchez. “Our mission for Clean Earth’s aerosol services directly align with our goals for sustainability – to ultimately go green as a company and for zero components to end up in a landfill. We’re committed to providing a 100% sustainable solution for aerosol waste for our customers and remaining a cutting-edge vendor with market-leading technology features.”

Clean Earth provides remediation, disposal, recycling and beneficial reuse solutions for contaminated soil, dredged material and hazardous and non-hazardous wastes, with the unique capability of providing a one-source, full-service recycling solution to handle multiple waste streams from a single customer. By turning specialty waste into recycling opportunities, Clean Earth creates a better future for all people, the planet and its customers.

Click here for a recent recording of the “Aerosol Recycling Solutions & Regulatory Update Webinar,” presented by Clean Earth’s Howard Ray, Business Development, and Wade Scheel, Director Governmental Affairs.

To learn more about Clean Earth, please visit www.cleanearthinc.com or follow the Company on Facebook, Twitter, LinkedIn or Instagram.

About Clean Earth

Clean Earth’s vision is to create a better future for our people, partners, and planet by turning specialty waste into recycling opportunities. Clean Earth is one of the largest specialty waste companies in the United States providing remediation, disposal, recycling, and beneficial reuse solutions for hazardous and non-hazardous waste and contaminated materials. Headquartered in Hatboro, Pennsylvania, it operates a network of 89 facilities. As a leader in the industry, Clean Earth has the experience and capabilities to provide efficient, effective waste recycling and disposal solutions. Our vast portfolio of technologies and services touches nearly every industry that generates waste including energy, infrastructure, commercial, industrial, retail, and healthcare markets.

About Harsco Corporation

Harsco Corporation is a global market leader providing environmental solutions for industrial and specialty waste streams, and innovative technologies for the rail industry. Based in Camp Hill, PA, the 13,000-employee company operates in more than 30 countries. Harsco’s common stock is a component of the S&P SmallCap 600 Index and the Russell 2000 Index. Additional information can be found at www.harsco.com.

Investor Contact Media Contact
David Martin Jay Cooney
717.612.5628 717.730.3683

[email protected]

[email protected]

Cambridge University Medical School Study: Rapid Medical Tourniquet More Conducive For Civilian Every Day Carry

Salt Lake City Utah, Nov. 12, 2020 (GLOBE NEWSWIRE) — Cambridge University Medical School Study Finds Rapid Medical Tourniquet More Conducive For Civilian Every Day Carry

Rapid Medical is pleased to share the Cambridge University Medical School findings of a study recently conducted in June of 2020 on the efficacy of commercial tourniquet designs for extremity hemorrhage control compared to a military-approved tourniquet. This study, which includes the Rapid Medical Tourniquet, clearly evaluates the Rapid Medical Tourniquet’s competency without bias.

“This study plainly states what we here at Rapid Medical have known for years; the Rapid Tourniquet is FAST and easy to apply while also being one of the most effective tourniquets to successfully stop arterial bleeding available. The Rapid Tourniquet is simple, lightweight, easy to apply to adults, children, and pets. No other tourniquet is as adaptable, making it the obvious choice for civilian carry, including families.” Stated Clint Chamberlain, Retired Army Captain, Veteran SLCPD Officer, Chief Operating Officer of Rapid Medical.

The study, conducted by nine emergency medicine residents, evaluated four different tourniquet designs.

Gen 7 Combat Application Tourniquet (CAT7; control) Stretch Wrap and Tuck Tourniquet (SWAT-T)
Gen 2 Rapid Application Tourniquet System (RATS)

Tourni-Key (TK)

Popliteal artery flow cessation was determined using a ZONARE ZS3 ultrasound. The steady-state maximal generated force was measured for 30 seconds with a thin-film force sensor.

Success rates for distal arterial flow cessation were: 89% CAT7
67% SWAT-T
89% RATS

78% TK (H 0.89; P = .83)


Mean (SD) application times were:
10.4 (SD = 1.7) seconds CAT7
23.1 (SD = 9.0) seconds SWAT-T
11.1 (SD = 3.8) seconds RATS
20.0 (SD = 7.1) seconds TK
(F 9.71; P <.001).

Steady state maximal forces were: 29.9 (SD = 1.2) N CAT7
23.4 (SD = 0.8) N SWAT-T
33.0 (SD = 1.3) N RATS
and 41.9 (SD = 1.3) N TK.

Conclusion: All commercial TQ systems were non-inferior to the military-approved CAT7. Mean application times were less than 30 seconds for all four designs. The size of these commercial TQs may make them more conducive to lay- provider EDC, thereby increasing community resiliency and improving the response to high-threat events. The study can be accessed here: The Efficacy of Novel Commercial Tourniquet Designs for Extremity Hemorrhage Control: Implications for Spontaneous Responder Every Day Carry.

  

About Rapid Medical 

The Rapid Tourniquet was developed to be used in real-life situations, under stress,including low-light/night. It is the only tourniquet on the market that works on adults, children, and pets. Unlike traditional tourniquets, there’s no threading, locks, or other complex procedures, just wrap around the limb and cleat off. The Rapid tourniquet is simple and easy-to-use, even one-handed. It is the fastest tourniquet available and can be rapidly and effectively implemented in military, law enforcement as well as civilian emergency medicine as a life-saving tool. Rapid Medical is Veteran owned and operated. To Learn more visit rapidtq.com

For more information please contact Sara Liberte [email protected] 412.400.3978

Attachments

Sara Liberte
MyMedic
412-400-3978
[email protected]

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tactile Systems Technology, Inc. – TCMD

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Tactile Systems Technology, Inc. (“Tactile” or the “Company”) (NASDAQ: TCMD).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. 

The investigation concerns whether Tactile and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On March 20, 2019, aftermarket hours, an amended federal qui tam complaint filed against Tactile by one of the Company’s competitors and pending in the Southern District of Texas was unsealed.  The qui tam complaint contained detailed allegations of illegal sales practices on the part of Tactile, causing the Company to submit fraudulent claims to Medicare and the Veteran’s Administration.  Specifically, the qui tam complaint accused Tactile of illegally paying hospital staff to induce physicians to prescribe its medical devices.  The qui tam complaint further alleged that the Company had violated anti-kickback laws by paying physicians to be “advisors” and “paid spokesmen” when these financial relationships were merely a way to secure those doctors’ business.  

On this news, Tactile’s stock price fell $4.53 per share over the next two trading days, or 7.5%, to close at $55.57 per share on March 22, 2019. 

Then, on February 21, 2020, the court issued an order in the qui tam action, denying Tactile’s motion to dismiss the complaint in its entirety.  On this news, Tactile’s stock price fell $6.65 per share, or 10.59%, to close at $56.09 per share on February 24, 2020.  Finally, on June 8, 2020, the research firm OSS Research (“OSS”) published a report about the Company entitled “Strong Sell on Tactile Systems: Bloated Stock Needs Compression Therapy.”  In the report, OSS accused Tactile of (1) overstating its total addressable market by nearly $4.7 billion, (2) using a “‘daisy-chaining kickback scheme’ that has resulted in rampant overprescribing and rapid market share gains at the expense of patients, insurers and the public,” and (3) concealing Medicare audits resulting in denials, for failure to establish medical necessity, of 71% of Tactile’s submitted claims. 

On this news, the Company’s stock price fell $6.05 per share, or 11.69%, to close at $45.67 per share on June 9, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

Voyager Sopris Learning Announces ‘Dr. Louisa Moats Award’

Created to Celebrate Schools, Districts Teaching Literacy Based on Science of Reading

DALLAS, Nov. 12, 2020 (GLOBE NEWSWIRE) — Voyager Sopris Learning today launched the first-ever “Dr. Louisa Moats Award for Excellence Implementing the Science of Reading.” Nominations are open now for the award, which seeks out and celebrates schools and districts for their excellence using the science of reading and Voyager Sopris Learning’s LETRS literacy professional learning solution.

The award is named in honor of internationally recognized literacy expert, Dr. Louisa Moats, who has been a leader in researching and advocating for professional development in the science of reading. She has inspired a generation of education leaders, teachers, and students to improve literacy achievement and reading success for all students. Dr. Moats is co-author of LETRS(Language Essentials for Teachers of Reading and Spelling), the landmark evidence-based professional learning that prepares educators for the challenging work of teaching literacy.

Dr. Moats said she is honored to be part of an award that will discover and call attention to “all those wonderful educators out there who have taken information about reading science and made it visible in school programs, policies, practices, and outcomes.”

Nominees are asked to submit video or written answers to four key areas of the award criteria, including how LETRS has transformed the applicant’s literacy teaching strategies and instruction. The nomination period closes Feb. 15, 2021; award recipients will be announced at a virtual event on March 31, 2021.

“The winning district must have strong leaders who have ‘owned’ the challenge and who aspire to get all kids reading,” Dr. Moats said. “It must also have a core group of teachers who have dug into substantive learning about reading science, who have been willing to change and improve, and who are working hard to refine their teaching skills.”

Dr. Moats, who earned a doctoral degree in reading and human development from Harvard University Graduate School of Education, said her admiration for educators knows no bounds.

“Teaching is hard and change is hard. It may involve letting go of dearly held beliefs or familiar programs and activities and replacing them with new understandings and practices,” Dr. Moats said. “So educators need every positive incentive to do that. Most importantly, kids’ lives are at stake here. Those schools and districts that are working to ensure that everyone learns to read must be celebrated so that others will follow their lead.”

The school or district that earns the grand prize will receive $5,000, a trophy inscribed with the recipient’s name and certificate of award, as well as 30 LETRS Champion T-shirts and 30 LETRS Champion journals. Two runners-up will be announced as well.

LETRS is relied upon nationally by thousands of educators, and this award will extend Dr. Moats’ legacy by honoring the work of an institution in the U.S. that has made a significant, transformational contribution toward the improvement of student literacy,” said John Campbell, CEO of Cambium Learning Group, parent company of Voyager Sopris Learning. “We want to shine a light on the hard-working educators who embody her dedication to literacy education excellence. The schools using LETRS and the science of reading are improving literacy for their students and, in doing so, are honoring Dr. Moats’ lifelong, groundbreaking work.”

For more information on the “Dr. Louisa Moats Award for Excellence Implementing the Science of Reading,” as well as a video message from Dr. Moats, visit www.voyagersopris.com/louisa-moats-award.

About Voyager Sopris Learning

Voyager Sopris Learning® is an education partner committed to unlocking the full potential of every teacher and every student. We believe that the best way to meet and exceed standards in education is to address the underlying systems of teaching and learning, and to nurture those systems at their most fundamental levels. Our programs and services are based on research and classroom evidence, ensuring they are easy to implement, teacher friendly and effective. We offer a variety of digital and blended instructional tools, programs, and professional learning, all of which are designed to help every teacher deliver nothing short of the highest-quality instruction to every student. Voyager Sopris Learning is a business unit of Cambium Learning® Group, Inc.

For more information, visit www.voyagersopris.com, or find us on Facebook or Twitter.

About Cambium Learning Group, Inc.

Cambium Learning® Group is the education essentials company, providing award-winning education technology and services for K-12 markets. With an intentionally curated portfolio of respected global brands, Cambium serves as a leader in the education space, helping millions of educators and students feel more universally valued each and every day. In everything it does, the company focuses on the elements that are most essential to the success of education, delivering simpler, more certain solutions that make a meaningful difference right now. To learn more, visit www.cambiumlearning.com or follow Cambium on Facebook, LinkedIn, Twitter, and Medium.

The Cambium family of companies includes: Cambium Assessment, Rosetta Stone®, Lexia® Learning, Learning A-Z®, Voyager Sopris Learning®, ExploreLearning®, Time4Learning®, and Kurzweil Education®

Media Contacts
:

Voyager Sopris Learning, Inc.
Ileana Rowe, Senior Vice President of Marketing
503.810.5183
[email protected]

Doug Thompson
Thompson Drake Public Relations
541.419.4471
[email protected]

 

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of First American Financial Corporation – FAF

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of First American Financial Corporation (“First American” or the “Company”) (NYSE: FAF).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether First American and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On May 24, 2019, KrebsOnSecurity reported that First American’s website “leaked hundreds of millions of documents related to mortgage deals going back to 2003.”  The records included bank account numbers and statements, mortgage and tax records, Social Security numbers, wire transaction receipts, and driver’s license images-all of which “were available without authentication to anyone with a Web browser.”  Approximately 885 million records were exposed. 

On this news, First American’s stock price fell $3.31 per share, or 6%, to close at $49.52 per share on May 27, 2019. 

Then, on October 22, 2020, after the market closed, First American disclosed receipt of a Wells Notice from the U.S. Securities and Exchange Commission (“SEC”), regarding a preliminary determination to file an enforcement action against the Company related to the security breach.  Specifically, the SEC questioned the adequacy of the Company’s disclosures at the time of the incident and the adequacy of its disclosure controls. 

On this news, First American’s stock price fell $4.83 per share, or 9.36%, to close at $46.75 per share on October 22, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

MicroEJ Supports QNX Neutrino Realtime Operating System (RTOS) to Accelerate Development of Mission-Critical Devices

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — MicroEJ, a leader in trusted virtual execution environments for cost effective SoC/MCU/MPU, today announced support for the QNX® Neutrino® RTOS, a microkernel real-time operating system from BlackBerry QNX. The QNX operating system is widely used in life and safety-critical systems for vehicles, medical devices, industrial controls, rail, robotics and aerospace & defense. With reliability being the essence of both partners, this collaboration empowers mission-critical device manufacturers with first-class safety, reduced R&D costs and faster time to production.

MICROEJ VEE standard micro-virtualization (less than 50Kb) completes the high performance and enhanced kernel-level security in the QNX RTOS by offering a closed and hermetic sandbox, which isolates and decouples certified software modules from less critical ones. This virtualized and modular architecture greatly eases system certification and ensures that best-effort code won’t be able to interact with the device critical functions.

In addition, binary software modules developed for MicroEJ VEE can be ported on any QNX supported hardware with no modification, resulting in reduced development costs, a scalable binary software foundation, and reduced software architecture complexity. Through its unique true binary code simulation on virtual devices, the combination of MicroEJ and BlackBerry QNX technologies addresses the number one embedded system issue: time-to-market for mission-critical and life-critical devices in markets such as medical, automotive, and industrial automation.

MICROEJ VEE supports QNX® Neutrino® RTOS v6.x and v7.x (including new features such as ASLR) for any available microcontroller, microprocessor, or systems-on-chip based on the latest ARMv8 architecture such as Cortex-R52, Cortex-M33, Cortex-M23 and legacy ones such as ARMv5.

Reliability, which is based on both safety and security paradigms, has always been our first and foremost priority, considering the sensitive nature of the millions of embedded devices powered by MicroEJ on the field today,” declares Fred Rivard, MicroEJ’s CEO. “With BlackBerry QNX technology, MicroEJ offers the best cost-effective process for mission-critical devices’ makers, allowing utmost levels of safety, and up to 70% time-to-market improvement, which is absolutely crucial due to the accelerating race to innovation today.”


We’re thrilled
to expand
our
collaboration with MicroEJ
. We
both
share
a
passion for innovation and reliability
and look forward to helping
mission-critical device manufacturer
s
expedite their IoT projects without sacrificing safety
or
security
,
said Grant Courville, VP, Products and Strategy, BlackBerry QNX.


About MicroEJ

MicroEJ is a software vendor of cost-driven solutions for embedded and IoT devices. We are focused on providing device manufacturers with secure products in markets where software applications require high performance, compact size, energy efficiency, and cost-effective development.

Today more than 120+ companies in the world with currently over 37 million products sold, have already chosen MicroEJ to design electronic product applications in a large variety of industries, including smart home, wearables, healthcare, industrial automation, retail, telecommunications, smart city, building automation, transportation, etc.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14926c47-e88a-4748-baec-89e9c3de42f9

For more info: www.microej.com
Media Contact: [email protected]

AMMO, Inc. Provides 3rd Quarter Fiscal Year 2021 Guidance Reflecting a Year-Over-Year 435% Revenue Increase

SCOTTSDALE, AZ, Nov. 12, 2020 (GLOBE NEWSWIRE) — AMMO, Inc. (OTCQB: POWW) (“AMMO” or the “Company”), a premier American ammunition and munition components manufacturer and technology leader, is pleased to provide guidance for its 3rd quarter for the 2021 Fiscal Year. 

The Company has updated its guidance for the 3rd quarter of fiscal year 2021 to approximately $15.0 million in revenue. AMMO’s 3rd quarter guidance represents an estimated 435% year-over-year increase compared to $2.8 million in revenue for the third quarter of fiscal 2020 and a 25% increase in revenue when compared to $12 million in the 2nd quarter of fiscal 2021.

“Our team continues to work diligently to meet existing domestic consumer demand as export opportunities start to open up again in the post-COVID international market. These efforts have kept us on track to increase our positive adjusted EBITDA in the fiscal 3rd quarter as we maintain our focus on driving sales for our higher margin product offerings,” said Fred Wagenhals, AMMO’s CEO.

About AMMO, Inc.

AMMO was founded in 2016 with a vision to change, innovate and invigorate the complacent munitions industry. The Company designs and manufactures products for a variety of markets, including law enforcement, military, hunting, sport shooting and self-defense. AMMO promotes its company branded munitions, its patented STREAK™ Visual Ammunition, /stelTH/™ subsonic munitions, and O.W.L. Technologies®. The Company’s corporate offices are headquartered in Scottsdale, Arizona. Manufacturing operations are based in both northern Arizona and Manitowoc, Wisconsin. For more information please visit: www.ammoinc.com.

Forward Looking Statements

This document contains certain “forward-looking statements”. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies, goals and objectives of management for future operations; any statements concerning proposed new products and services or developments thereof; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

Forward looking statements may include the words “may,” “could,” “estimate,” “intend,” “continue,” “believe,” “expect” or “anticipate” or other similar words, or the negative thereof. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures and risk factors we include in Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Reports filed on Form 8-K.

Investor Contact:

Rob Wiley, CFO
AMMO, Inc.
Phone: (480) 947-0001
[email protected]

Cambridge University Medical School Study: Rapid Medical Tourniquet More Conducive For Civilian Every Day Carry

Salt Lake City Utah, Nov. 12, 2020 (GLOBE NEWSWIRE) — Cambridge University Medical School Study Finds Rapid Medical Tourniquet More Conducive For Civilian Every Day Carry

Rapid Medical is pleased to share the Cambridge University Medical School findings of a study recently conducted in June of 2020 on the efficacy of commercial tourniquet designs for extremity hemorrhage control compared to a military-approved tourniquet. This study, which includes the Rapid Medical Tourniquet, clearly evaluates the Rapid Medical Tourniquet’s competency without bias.

“This study plainly states what we here at Rapid Medical have known for years; the Rapid Tourniquet is FAST and easy to apply while also being one of the most effective tourniquets to successfully stop arterial bleeding available. The Rapid Tourniquet is simple, lightweight, easy to apply to adults, children, and pets. No other tourniquet is as adaptable, making it the obvious choice for civilian carry, including families.” Stated Clint Chamberlain, Retired Army Captain, Veteran SLCPD Officer, Chief Operating Officer of Rapid Medical.

The study, conducted by nine emergency medicine residents, evaluated four different tourniquet designs.

Gen 7 Combat Application Tourniquet (CAT7; control) Stretch Wrap and Tuck Tourniquet (SWAT-T)
Gen 2 Rapid Application Tourniquet System (RATS)

Tourni-Key (TK)

Popliteal artery flow cessation was determined using a ZONARE ZS3 ultrasound. The steady-state maximal generated force was measured for 30 seconds with a thin-film force sensor.

Success rates for distal arterial flow cessation were: 89% CAT7
67% SWAT-T
89% RATS

78% TK (H 0.89; P = .83)


Mean (SD) application times were:
10.4 (SD = 1.7) seconds CAT7
23.1 (SD = 9.0) seconds SWAT-T
11.1 (SD = 3.8) seconds RATS
20.0 (SD = 7.1) seconds TK
(F 9.71; P <.001).

Steady state maximal forces were: 29.9 (SD = 1.2) N CAT7
23.4 (SD = 0.8) N SWAT-T
33.0 (SD = 1.3) N RATS
and 41.9 (SD = 1.3) N TK.

Conclusion: All commercial TQ systems were non-inferior to the military-approved CAT7. Mean application times were less than 30 seconds for all four designs. The size of these commercial TQs may make them more conducive to lay- provider EDC, thereby increasing community resiliency and improving the response to high-threat events. The study can be accessed here: The Efficacy of Novel Commercial Tourniquet Designs for Extremity Hemorrhage Control: Implications for Spontaneous Responder Every Day Carry.

  

About Rapid Medical 

The Rapid Tourniquet was developed to be used in real-life situations, under stress,including low-light/night. It is the only tourniquet on the market that works on adults, children, and pets. Unlike traditional tourniquets, there’s no threading, locks, or other complex procedures, just wrap around the limb and cleat off. The Rapid tourniquet is simple and easy-to-use, even one-handed. It is the fastest tourniquet available and can be rapidly and effectively implemented in military, law enforcement as well as civilian emergency medicine as a life-saving tool. Rapid Medical is Veteran owned and operated. To Learn more visit rapidtq.com

For more information please contact Sara Liberte [email protected] 412.400.3978

Attachments

Sara Liberte
MyMedic
412-400-3978
[email protected]